帕金森病的药物治疗
Drug management of Parkinson's disease.
作者信息
Kishore A, Snow B J
机构信息
Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre, BC.
出版信息
Can Fam Physician. 1996 May;42:946-52.
Abstract
Levodopa remains the cornerstone for managing Parkinson's disease. Physician's preference usually determines the dopamine agonist chosen for the early phases of treatment. The concept of neuro-protection, however, remains unproven. A better understanding of the cause of the disease and treatment-related complications could make managing Parkinson's disease more rewarding.
摘要
左旋多巴仍然是治疗帕金森病的基石。医生的偏好通常决定了在治疗早期阶段所选用的多巴胺激动剂。然而，神经保护的概念仍未得到证实。更好地了解该疾病的病因和与治疗相关的并发症，可能会使帕金森病的治疗更有成效。
相似文献
1
Drug management of Parkinson's disease.帕金森病的药物治疗
Can Fam Physician. 1996 May;42:946-52.
2
Treatment of Parkinson's disease.帕金森病的治疗。
Aust Fam Physician. 1995 Sep;24(9):1685-7, 1690-2.
3
Treatment options for early Parkinson's disease.早期帕金森病的治疗选择。
Am Fam Physician. 1996 Mar;53(4):1281-7.
4
Parkinson's disease: managing symptoms and preserving function.帕金森病：症状管理与功能维持
Geriatrics. 1995 Sep;50(9):24-31.
5
[Optimization of the treatment of Parkinson's disease using dopamine agonists].[使用多巴胺激动剂优化帕金森病治疗]
Arch Neurobiol (Madr). 1991 Nov-Dec;54(6):282-7.
6
Current therapy of Parkinson's disease.帕金森病的当前治疗方法。
Iowa Med. 1997 Jan;87(1):27-9.
7
New concepts in the treatment of Parkinson's disease.帕金森病治疗的新概念。
Am Fam Physician. 1990 Feb;41(2):574-84.
8
Treatment of Parkinson's disease. From theory to practice.帕金森病的治疗。从理论到实践。
Postgrad Med. 1994 Apr;95(5):52-4, 57-8, 61-4 passim.
9
Moderate Parkinson's disease. Strategies for maximizing treatment.中度帕金森病。优化治疗的策略。
Postgrad Med. 1996 Jan;99(1):52-4, 61-3, 67-8, passim.
本文引用的文献
1
A clinicopathologic study of 100 cases of Parkinson's disease.100例帕金森病的临床病理研究
Arch Neurol. 1993 Feb;50(2):140-8. doi: 10.1001/archneur.1993.00540020018011.
2
Individualizing therapy in patients with disabling Parkinson's disease symptoms.对帕金森病致残症状患者进行个体化治疗。
Neurology. 1994 Mar;44(3 Suppl 1):S8-11.
3
Treating motor fluctuations with controlled-release levodopa preparations.使用控释左旋多巴制剂治疗运动波动。
Neurology. 1994 Jul;44(7 Suppl 6):S23-8.
4
Multi-center study of Parkinson mortality with early versus later dopa treatment.早期与晚期多巴治疗帕金森病死亡率的多中心研究。
Ann Neurol. 1987 Jul;22(1):8-12. doi: 10.1002/ana.410220105.
5
Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet).帕金森病与运动波动：长效卡比多巴/左旋多巴（控释息宁）
Neurology. 1987 May;37(5):875-8. doi: 10.1212/wnl.37.5.875.
6
Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up.溴隐亭与左旋多巴早期联合治疗帕金森病：5年随访
Neurology. 1987 May;37(5):826-8. doi: 10.1212/wnl.37.5.826.
7
[3H]imipramine binding sites are decreased in platelets of chronic pain patients.慢性疼痛患者血小板中[3H]丙咪嗪结合位点减少。
Clin Neuropharmacol. 1987 Apr;10(2):175-7. doi: 10.1097/00002826-198704000-00008.
8
"Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease.左旋多巴治疗的“早期”启动并不会促进帕金森病患者出现运动反应波动、异动症或痴呆。
Neurology. 1991 May;41(5):622-9. doi: 10.1212/wnl.41.5.622.
9
The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic.司来吉兰的抗帕金森病疗效源于可能是对症的短暂改善。
Ann Neurol. 1992 Dec;32(6):795-8. doi: 10.1002/ana.410320614.
Zotero 插件